Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:603882'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -174.33 Med: 27.25 Max: 76.33
Current: 18.57
During the past 12 years, the highest EV-to-EBITDA of Guangzhou Kingmed Diagnostics Group Co was 76.33. The lowest was -174.33. And the median was 27.25.
SHSE:603882's EV-to-EBITDA is ranked worse than 57.36% of 129
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.49
vs SHSE:603882: 18.57
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Guangzhou Kingmed Diagnostics Group Co's PE Ratio (TTM) for today is calculated as:
Guangzhou Kingmed Diagnostics Group Co's share price for today is ¥28.76.
Guangzhou Kingmed Diagnostics Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.224.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Kingmed Diagnostics Group Co EV-to-EBITDA Chart
Guangzhou Kingmed Diagnostics Group Co Annual Data
SHSE:603882 vs TMO, DHR, NTRA: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Guangzhou Kingmed Diagnostics Group Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Kingmed Diagnostics Group Co EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guangzhou Kingmed Diagnostics Group Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Guangzhou Kingmed Diagnostics Group Co's EV-to-EBITDA falls into.
Guangzhou Kingmed Diagnostics Group Co's current Enterprise Value is ¥12,076 Mil.
Guangzhou Kingmed Diagnostics Group Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥650 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) has a EV-to-EBITDA of 18.57 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Guangzhou Kingmed Diagnostics Group Co. This is 32% below median its historical median of 27.25. According to the industry distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #74 out of 129 companies in the Medical Diagnostics & Research industry, placing it in the top 57.4%.
Is Guangzhou Kingmed Diagnostics Group Co's EV-to-EBITDA too high?
Guangzhou Kingmed Diagnostics Group Co's current EV-to-EBITDA of 18.57 is 32% below median its 10-year median of 27.25. The Medical Diagnostics & Research industry median EV-to-EBITDA is 16.49. Guangzhou Kingmed Diagnostics Group Co's value of 18.57 is 12.6% above this industry median. Based on the distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #74 out of 129 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Guangzhou Kingmed Diagnostics Group Co has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Kingmed Diagnostics Group Co's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #74 out of 129 companies for EV-to-EBITDA. This places Guangzhou Kingmed Diagnostics Group Co in the lower half of its industry. The industry median EV-to-EBITDA is 16.49. Guangzhou Kingmed Diagnostics Group Co's value of 18.57 is 12.6% above this benchmark. While the company's 10-year median is 27.25 vs. the industry median of 16.49, Guangzhou Kingmed Diagnostics Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 16.49, based on 129 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangzhou Kingmed Diagnostics Group Co's current EV-to-EBITDA of 18.57 is 12.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Guangzhou Kingmed Diagnostics Group Co. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 16.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Kingmed Diagnostics Group Co's current EV-to-EBITDA is 18.57, which is 32% below median its own 10-year median of 27.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Kingmed Diagnostics Group Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) is currently considered Fairly Valued. The stock's GF Value™ is ¥28.65, compared to a current price of ¥28.76 — trading 0.4% above its estimated fair value. The current EV-to-EBITDA is 18.57, which is 32% below median its 10-year median of 27.25 and 12.6% above the Medical Diagnostics & Research industry median of 16.49. Guangzhou Kingmed Diagnostics Group Co's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Guangzhou Kingmed Diagnostics Group Co (SHSE:603882), the current EV-to-EBITDA is 18.57 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co stock appears to be overvalued.
The current stock price of ¥28.76 is trading 0.4% above its estimated GF Value™ of ¥28.65.
GuruFocus considers Guangzhou Kingmed Diagnostics Group Co to be Fairly Valued.
Key valuation signals for SHSE:603882:
EV-to-EBITDA: 18.57 (32% below median its 10-year median of 27.25)
GF Value™: ¥28.65 vs. price of ¥28.76 (0.4% above fair value)
Industry Position: 12.6% above the Medical Diagnostics & Research median (#74 of 129)
No single metric tells the full story. See the SHSE:603882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 1994, KingMed is the largest independent clinical laboratory in China. It was listed on the Shanghai Stock Exchange in 2017. As of 2024, KingMed has 50 centralized labs and provides over 4000 test items. Over 90% of its total revenue comes from clinical diagnostics. Furthermore, KingMed has been actively investing in its cold chain logistics. Its service network covers the most intensely populated areas in China.
77GF Score
Get the complete analysis for SHSE:603882
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603882 has been successfully added to your 
